- Home
- DOUG vs UNCY Comparison
DOUG vs UNCY Comparison
Compare DOUG & UNCY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | DOUG | UNCY |
|---|---|---|
| Founded | 1911 | 2016 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Building operators | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 145.4M | 150.1M |
| IPO Year | 2021 | 2021 |
Fundamental Metrics
Financial Performance| Metric | DOUG | UNCY |
|---|---|---|
| Price | $1.47 | $3.35 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 10 |
| Target Price | N/A | ★ $28.40 |
| AVG Volume (30 Days) | 516.8K | ★ 849.1K |
| Earning Date | 11-02-2026 | 11-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 118.68 | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $955,578,000.00 | $675,000.00 |
| Revenue This Year | $0.59 | N/A |
| Revenue Next Year | $7.00 | $10,812.60 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $1.42 | $3.56 |
| 52 Week High | $3.03 | $8.74 |
Technical Indicators
Market Signals| Indicator | DOUG | UNCY |
|---|---|---|
| Relative Strength Index (RSI) | 35.31 | 19.15 |
| Support Level | N/A | N/A |
| Resistance Level | $1.84 | $5.86 |
| Average True Range (ATR) | 0.06 | 0.20 |
| MACD | 0.00 | -0.07 |
| Stochastic Oscillator | 23.68 | 0.72 |
Price Performance
Historical ComparisonAbout DOUG Douglas Elliman Inc.
Douglas Elliman Inc is engaged in the real estate services business and seeks to acquire or invest in additional real estate services businesses. The Company also offers, through its subsidiaries and ventures, development marketing services and ancillary services, including mortgage, title, and escrow services. It generates revenue from commissions and other brokerage income, property management, and other ancillary services.
About UNCY Unicycive Therapeutics Inc.
Unicycive Therapeutics Inc is a clinical-stage biotechnology company focused on identifying, developing, and commercializing therapies to address unmet medical needs, with a primary focus on kidney disease. The company is advancing two key product candidates: oxylanthanum carbonate (OLC), a phosphate binder for the treatment of hyperphosphatemia in chronic kidney disease patients on dialysis, and UNI-494, a drug candidate for the treatment of acute kidney injury.